BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30717807)

  • 1. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
    Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
    Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ITGBL1 promotes migration, invasion and predicts a poor prognosis in colorectal cancer.
    Qiu X; Feng JR; Qiu J; Liu L; Xie Y; Zhang YP; Liu J; Zhao Q
    Biomed Pharmacother; 2018 Aug; 104():172-180. PubMed ID: 29772438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 7. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.
    Miyoshi J; Toden S; Yoshida K; Toiyama Y; Alberts SR; Kusunoki M; Sinicrope FA; Goel A
    Sci Rep; 2017 Mar; 7():43393. PubMed ID: 28262692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients.
    Zhang W; Zhang X; Zhao D; Hu M; Ge X; Xia L
    Dig Dis Sci; 2022 Nov; 67(11):5116-5126. PubMed ID: 35094253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive analysis of potential gastric cancer prognostic biomarker ITGBL1 associated with immune infiltration and epithelial-mesenchymal transition.
    Wang Z; Fu L; Zhang J; Ge Y; Guo C; Wang R; Deng M; Wang Q; Wang Z
    Biomed Eng Online; 2022 May; 21(1):30. PubMed ID: 35596183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
    Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
    Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
    Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IBSP, a potential recurrence biomarker, promotes the progression of colorectal cancer via Fyn/β-catenin signaling pathway.
    Chen Y; Qin Y; Dai M; Liu L; Ni Y; Sun Q; Li L; Zhou Y; Qiu C; Jiang Y
    Cancer Med; 2021 Jun; 10(12):4030-4045. PubMed ID: 33987980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
    Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
    Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular signature for the prediction of recurrence in colorectal cancer.
    Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
    Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
    Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
    Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.
    Sreekumar R; Harris S; Moutasim K; DeMateos R; Patel A; Emo K; White S; Yagci T; Tulchinsky E; Thomas G; Primrose JN; Sayan AE; Mirnezami AH
    JAMA Netw Open; 2018 Oct; 1(6):e183115. PubMed ID: 30646224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer.
    Kim SK; Kim SY; Kim CW; Roh SA; Ha YJ; Lee JL; Heo H; Cho DH; Lee JS; Kim YS; Kim JC
    Exp Mol Med; 2019 Oct; 51(10):1-12. PubMed ID: 31578316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a lipogenic genes panel for diagnosis and recurrence of colorectal cancer.
    Gharib E; Nasrinasrabadi P; Zali MR
    PLoS One; 2020; 15(3):e0229864. PubMed ID: 32155177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
    Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
    Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma.
    Huang W; Yu D; Wang M; Han Y; Lin J; Wei D; Cai J; Li B; Chen P; Zhang X
    Cell Prolif; 2020 Jul; 53(7):e12836. PubMed ID: 32537856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.